Flavogard

Tablet with Pycnogenol

Nature's Superantioxdant

Flavogard 50 mg tabletta
Flavogard bliszter
Flavogard back

What is the Active Ingredient in Flavogard?

Pycnogenol

Pycnogenol, Nature's Superantioxidant

Pycnogenol ®, the active ingredient in Flavogard,  is an aqueous extract of the bark of the French maritime pine (Pinus maritima), a complex containing active bioflavonoids and other substances in concentrated form and unchanged composition. Approx. 600 g of pine bark is required for the production (extraction) of one gramm of Pycnogenol ®, 

What is the Mechasim of Action of Flavogard?

1. Vasodilation via Increased Nitric Oxide Synthesis

After two weeks of Pycnogenol consumption (180 mg / day), vasodilation resulted in a 46% increase in blood flow from baseline in young healthy volunteers, which was significantly better than the ineffective placebo. The nitric oxide synthase inhibitor neutralized the effect of Pycnogenol. Nishioka et al., 2007. 1

Pycnogenol egyik hatásmechanizmusa az értágító nitrogénoxid termelésének növelése

2. Strengthening of Vascular Walls via Inhibition of Collagen Degradation

In clinical trials, Pycnogenol inhibited the activity of collagenase / elastase / hyaluronidase degrading enzymes, thereby protecting collagen / elastin from breaking down. 2

The strengthening of the vascular wall structure has contributed to the outcomes in clinical trials with Pycnogenol in several areas (eg venous insufficiency, diabetes, retinopathy, etc.).

A Pycnogenol gátolja a kollagén lebontását

3. Reduction of Inflammation via Reduced Production of Inflammatory Enzymes

Pycnogenol intervenes in the inflammatory cascade at the earliest possible stage by reducing the production of inflammatory enzymes (COX-2 in the joints, 5-LOX in the airways) 3. This has several advantages over standard anti-inflammatory drug therapy: less COX-2 causes fewer symptoms (e.g., pain, stiffness) which can be alleviated with less anti-inflammatory drugs resulting in less side effects.

A Pycnogenol csökkentette a gyulladásos enzímek gyártását

Hasonlóan, az 5-LOX csökkentett termelése  csökkenti a gyógyszerigényt és a mellékhatásokat, valamint javítja az életminőséget allergiában és asztmában

Who is Flavogard Recommended To?

A Dozen of Reasons to Take Flavogard

Increased the students’ examination results 1 , increased the cognitive performance of 35-55 year-old intellectuals 2, and the memory of elderly (60-85 year old) people 3.

Improved skin hydration (+ 8%), elasticity (+25%), increased synthesis of hyaluronic acid (+44%) and collagen (+29-41%). 4

Reduced the symptoms ofhay fever and asthma. 5, 6 In combination with vitamin C and zinc, reduced the incidence and duration of common cold symptoms. 7

 In combination with Q10, improved functional status (NYHA classfication)  (in 28% of patients), increased walking distance (by 230%) in patients with heart failure. 8

Reduced menstrual pain ( by 36%) 9, alleviated pain in 58% of endometriosis spatients 10, relieved postmenopausal symptoms 11

Pycnogenol was approx. twice as effective  as the most widely prescribed venoactive drug in reducing  the symptoms of varicose veins(pain, ankle swelling  heavy leg, redness). 12

Reduced the symptoms of psoriasis and shortened the treatment time (by 32%). 13

 In combination with an antidiabetic and antihypertensive agent, reduced all major cardiovascular risk factors in patients with type 2 diabetes . 14

Reduced pain (by 43%) and stiffness (by 35%) in patients with knee arthrosis. 15

In combination with L-arginine, normalized erectile function in men with mild-to-moderate erectile dysfunction. 16

Reduced the required dose of steroid inhaler in 55% of patients with asthma. 17

Reduced retinal bleeding 18 and retina swelling 19, improved visual acuity in patients with diabetic retinopathy 19.

Flavogard alkalmazási területei

Pycnogenol is one of the best researched natural substances in the world. Its benefits have been demonstrated in more than 250 clinical trials, often compared to the best available therapeutic option.

What Makes Flavogard Special?

Standard, Evidence-Based, Popular

Standard Product

  • a single standard extract from a single source made by a single manufacturer
  • no geographical or seasonal variations
  • Good Manufacturing practice (GMP)

Special Combination

  • nowhere else in nature are Pycnogenol’s specific procyanidins and unique blend of bioflavonoid nutrients found

Evidence-Based

  • 40 years of intensive research, approx. 100 clinical trials, approx. 250 scientific publications
Flavogard

Popular

  • more than 1000 Pycnogenol-based products in more than 100 countries worldwide

Quality

  • Flavogard is the first Pycnogenol-based product manufactured in Hungary 
  • Natural ingredients only, suitable for vegetarians.

References

  1. Nishioka K et al. Pycnogenol®, French Maritime Pine Bark Extract, Augments Endothelium-Dependent Vasodilation in Humans. Hypertens Res (2007) 30, 775–780
  2. Hörphag Research Ltd. Database
  3. Canali R et al.  The anti-inflammatory pharmacology of Pycnogenol® in humans involves COX-2 and 5-LOX mRNA expression in leukocytes. Int Immunopharmacol 2009 Sep; 9(10):1145-9

References: A Dozen of Reasons to Take Flavogard

  1. Panminerva Med 2011 Sep; 53 (3 Suppl 1): 75-82; 
  2. J Neurosurg Sci. 2014 Dec; 58( 4): 239-48; 
  3.  J Psychopharmacol 22(5) 553–562, 2008;
  4.  Skin Pharmacol Physiol 25:86-92, 2012; 
  5. Phytother Res; 24(8): 1115-1119, 2010; 
  6. Panminerva Medica 2011 Sep; 53 (Suppl. 1): 57-64;
  7.  Otorinolaringol. 2013 63(3):151-61; 
  8. Panminerva Med 2010;52(2Suppl1): 21-5; 
  9.  J Reprod Med 49(10): 828-832, 2004; 
  10.  J Reprod Med 2007 Aug;52(8):703-8; 
  11.  J Reprod Med 58: 39-46, 2013; 
  12.  Clin Appl Thrombosis/Hemostasis 12(2):205–212, 2006;
  13.  Panminerva Med 56 (1): 41-48, 2014 ;
  14.  Nutrition Research 28: 315-320, 2008; 
  15. Nutr Res 27: 692-697, 2007; 
  16. Int J Impot Res 2008 Mar-Apr; 20(2): 173-80 
  17. Panminerva Med 2011 Sep; 53 (Suppl. 1): 57-64 ;
  18. Phytother Res 15: 219-223, 2001;
  19. J Ocul Pharm Ther 25(6): 537-540, 2009.

Leave a Reply